Infliximab in the treatment of recalcitrant idiopathic orbital inflammation.
A 15-year-old boy had bilateral idiopathic orbital inflammation refractory to treatment with corticosteroids. He was not only unresponsive to subsequent therapy with methotrexate but also had elevation of serum liver enzymes. In an attempt to minimize further side effects of corticosteroids and to avoid external beam radiation in an adolescent, we began treatment with infliximab, an anti-tumor necrosis-alpha antibody. His symptoms resolved and his disease has not recurred. Use of infliximab may be useful in the treatment of recalcitrant idiopathic orbital pseudotumor.
Wilson
Matthew W
MW
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA. mwilson5@utmem.edu
Shergy
William J
WJ
Haik
Barrett G
BG
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D000069285:Infliximab; D008297:Male; D016727:Orbital Pseudotumor / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab